Diamond Biofund Inc.
- Company typePublic
- Founded2013
- HeadquartersTaipei, Taiwan
- Headcount11–50
- GTM typeB2B
- OfferingServices
Diamond Biofund Inc. firmographics
Firmographics- Name
- Diamond Biofund Inc.
- Legal name
- 鑽石生技投資股份有限公司
- Website
- https://diamondbiofund.com
- Company type
- Public
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Where Diamond Biofund Inc. is headquartered
LocationHeadquarters
- HQ city
- Taipei
- HQ country
- Taiwan
- HQ region
- Asia
Offices1 record
Markets served
Diamond Biofund Inc. business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations
Revenue model
- Investment Returns: As a venture capital firm, Diamond Biofund generates returns through capital appreciation and exit events from its portfolio of biotech investments. Revenue is primarily derived from changes in fair value of investments measured under IFRS.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Diamond Biofund Inc. product offering
Product offeringCore offering
Diamond Biofund Inc. is a venture capital and private equity firm that invests in life sciences, biotechnology, and healthcare companies. The firm manages two core venture capital funds (Diamond Biofund I and Diamond Biofund II) that provide equity capital to innovative biotech companies developing new drugs, high-end medical devices, healthcare services, and agricultural biotechnology. The firm leverages 25+ years of drug development experience to support portfolio companies from laboratory research through commercialization.
Product overview
Diamond Biofund Inc. is a sustainable biotech venture capital firm (永續型生技創投) that operates as a unified investment platform. The company manages two venture capital funds—Diamond Biofund I and Diamond Biofund II—and maintains a portfolio of approximately 11 biotech companies. The firm focuses on identifying and investing in top-tier biotech targets, providing comprehensive professional resources backed by over 25 years of new drug development experience, and working to build flagship biotech companies in partnership with major financial holding companies to achieve maximum investment returns.
Differentiator
Problem solved
Functional benefit
Products and services
- Diamond Biofund I (鑽石一號投資股份有限公司)
- Diamond Biofund II (鑽石高新投資股份有限公司)
Companies that use Diamond Biofund Inc.
Customer profileNamed customers5 records
Segments1 record
Ideal customer profiles1 record
Diamond Biofund Inc. technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Diamond Biofund Inc. partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Taiwan Stock ExchangecoreCo-host of the annual Asia Pacific Biotech Investment Forum, bringing together over 500 industry experts.
- Taipei ExchangecoreCo-host of the annual Asia Pacific Biotech Investment Forum with Taiwan Stock Exchange.
- Taiwan Bio-Development FoundationcoreFounded by Diamond Biofund to cultivate biomedical talent in Taiwan. Annual contributions of NT$20 million, with NT$100 million initial endowment. Has produced 160 PhD students, 270 master's students, and over 100 postdoctoral researchers.
- Taiwan Venture Capital AssociationminorDiamond Biofund serves as a director of the Taiwan Venture Capital Association and actively participates in association activities.
- Lovely Taiwan FoundationminorDiamond Biofund contributes NT$5 million annually to support community, cultural, educational, and arts programs in Nan-Zhou, Pingtung.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Diamond Biofund Inc. competitors and assessment
Company assessmentRegional players
- Taiwania Capital: Taiwan-based venture capital firm backed by National Development Council with a CVC mandate across technology and biotech. Comparable to Diamond Biofund as a domestic VC competitor focused on Taiwan biotech opportunities.
Direct peers
- RA Capital Management: Healthcare-focused investment firm with a venture and public-equity approach to biotech. Comparable to Diamond Biofund in deploying long-term capital across the biotech development cycle with deep sector expertise.
- Vivo Capital: US-based healthcare/biotech-focused venture capital firm with strong Asia-Pacific exposure. Comparable to Diamond Biofund in its life sciences investment thesis and focus on backing biotech companies through clinical and commercial milestones.
- Atlas Venture: Early-stage biotech venture capital firm that builds companies around academic science. Directly comparable in its model of providing both capital and operational resources to translate research into biotech products.
- OrbiMed Advisors: Leading global healthcare-dedicated investment firm spanning venture, growth, and public equities. Comparable to Diamond Biofund as a specialist biotech investor with multi-stage life sciences mandates and active portfolio support.
- ARCH Venture Partners: Pioneering US biotech VC firm that partners with leading academic institutions to launch and build biotech companies. Directly comparable to Diamond Biofund in leveraging academic talent networks to source and incubate new drug development opportunities.
- 5AM Ventures: US-based early-stage biotech venture capital firm. Comparable in its focused thesis on building biotech companies from academic research, similar to Diamond Biofund's "lab to market" positioning.
- Hotung Investment: Taiwan-listed venture capital firm (TWSE 3105) with a long-running technology/biotech investment focus. Closely comparable to Diamond Biofund as another publicly listed Taiwanese VC with a similar investment mandate and domestic shareholder base.
Broad incumbents
- Burrill & Company: Long-standing life sciences advisory and investment firm. Historically comparable to Diamond Biofund in its dedicated biotech investment and advisory franchise, though broader in scope.
- Temasek Holdings (Life Sciences): Singapore sovereign wealth investor with significant healthcare/biotech allocations across its portfolio. Broader in mandate but a relevant Asia-Pacific investor in life sciences, sharing Diamond Biofund's interest in regional biotech themes.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Diamond Biofund Inc. compliance and trust
Trust signalCompliance2 records
Diamond Biofund Inc. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Diamond Biofund Inc. leadership team
Management profileNumber of profiles
Profiles10 records
Diamond Biofund Inc. subsidiaries and ownership
Company hierarchySubsidiaries2 records
Diamond Biofund Inc. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Diamond Biofund Inc. M&A and investment
M&A and investmentM&A
Investments10 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Diamond Biofund Inc.
What does Diamond Biofund Inc. do?
Diamond Biofund Inc. is a venture capital and private equity firm that invests in life sciences, biotechnology, and healthcare companies. The firm manages two core venture capital funds (Diamond Biofund I and Diamond Biofund II) that provide equity capital to innovative biotech companies developing new drugs, high-end medical devices, healthcare services, and agricultural biotechnology. The firm leverages 25+ years of drug development experience to support portfolio companies from laboratory research through commercialization.
Is Diamond Biofund Inc. a public or private company?
Diamond Biofund Inc. is a public company. It is classified as public and is currently operating.
When was Diamond Biofund Inc. founded?
Diamond Biofund Inc. was founded in 2013. It employs 11 to 50 people.
Where is Diamond Biofund Inc. based?
Diamond Biofund Inc. is headquartered in Taipei, Taiwan, in the Asia region.
How does Diamond Biofund Inc. make money?
One revenue line is on record: investment Returns.
Who are Diamond Biofund Inc.'s main competitors?
Taiwania Capital is listed as a regional player. Direct peers are RA Capital Management, Vivo Capital, Atlas Venture, OrbiMed Advisors, ARCH Venture Partners, 5AM Ventures and Hotung Investment. Broad incumbents are Burrill & Company and Temasek Holdings (Life Sciences).
Does Diamond Biofund Inc. have an API?
No public API is recorded for Diamond Biofund Inc..